Reduced Rate of Neural Differentiation in the Dentate Gyrus of Adult Dysbindin Null (Sandy) Mouse by Nihonmatsu-Kikuchi, Naomi et al.
Reduced Rate of Neural Differentiation in the Dentate














1Mood Disorders Research Team, Tokyo Institute of Psychiatry, Tokyo, Japan, 2Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, 3The
Osaka-Hamamatsu Joint Research Center for Child Mental Development, Graduate School of Medicine, Osaka University, Osaka, Japan, 4Department of Psychiatry, Osaka
University Graduate School of Medicine, Osaka, Japan, 5Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and
Psychiatry, Tokyo, Japan, 6Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University, Osaka, Japan, 7Department of Child Development
and Molecular Brain Science, United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Osaka,
Japan
Abstract
Genetic variations in the gene encoding dysbindin has consistently been associated with schizophrenia and bipolar
disorder, although little is known about the neural functions carried out by dysbindin. To gain some insight into this area,
we took advantage of the readily available dysbindin-null mouse sandy (sdy2/2) and studied hippocampal neurogenesis
using thymidine analogue bromodeoxuridine (BrdU). No significant differences were found in the proliferation (4 hours) or
survival (1, 4 and 8 weeks after the last BrdU injection) of progenitors in the subgranular regions of the dentate gyrus
between sdy2/2 and sdy+/+ (control) mice. However, 4 weeks after the last BrdU injection, a significant reduction was
observed in the ratio of neuronal differentiation in sdy2/2 when compared to that of sdy+/+ (sdy+/+ =87.065.3% vs.
sdy2/2 =71.368.3%, p=0.01). These findings suggest that dysbindin plays a role during differentiation process in the
adult hippocampal neurogenesis and that its deficit may negatively affect neurogenesis-related functions such as cognition
and mood.
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Introduction
The dysbindin-1 gene (dystrobrevin-binding protein 1) was
originally identified as a gene associated withschizophreniathrough
its linkage to chromosome 6p [1]. Several subsequent studies have
replicated the association between this locus and schizophrenia. In
addition, two recent and independent reports have linked certain
dysbindin-1 risk haplotypes with bipolar disorder [2,3].Dysbindin-1
is widely distributed in the brain, and has been detected both pre-
and post-synaptically [4]. A recent immunoelectron microscopy
study further revealed that, in the hippocampus, dysbindin-1 is
located in synaptic vesicles of axospinous terminals in the dentate
gyrus inner molecular layer (DGiml) and CA1 stratum radiatum
and in postsynaptic densities and microtubules of dentate hilus
neurons and CA1 pyramidal cells [5].
To date, no amino acid sequence mutation in the dysbindin-1
protein that might contribute to the risk of major psychosis has been
identified. Furthermore, several studies have implicated the involve-
ment of many different alleles and haplotypes as susceptibility variants.
Thesepolymorphisms,however,may modulatedysbindin-1expression
levels since reduced dysbindin message and/or protein levels have been
found in schizophrenic brains such as prefrontal cortex and
hippocampal formation, brain areas commonly affected by the
disorder [6,7,8]. In the hippocampus of schizophrenic patients,
dysbindin-1 reductions occur in the synaptic terminal fields of
glutamatergic neurons, especially those located in the DGiml [7].
Although its function in the brain is still not well understood, it
may play a role in both glutamatergic and dopaminergic
neurotransmission [9,10,11]. For example, knockdown of endoge-
nous dysbindin with siRNA has been shown to reduce glutamate
levels in cultured neurons, suggesting that a decrease in dysbindin
levels has synaptic consequences [7,10]. Furthermore, altered
dysbindin-1 expression may contribute to cognitive impairments
prominent in schizophrenia, including deficits in attention, memory
and executive function [12–14]. More recently, ‘‘sandy’’ (sdy2/2)
mice, spontaneously occurring dysbindin null mice, have been
shown to exhibit a number of behavioral abnormalities associated
with reductions in forebrain dopamine transmission [15,16].
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15886In the presentstudy, we investigated the adult neurogenesis in the
dentate gyrus (DG) of the hippocampus in syd2/2 mice, in order
to further understand the roles of dysbindin-1 in the pathogenesis of
major psychosis. We found that sdy2/2 mice exhibit significantly
reduced rate of neuronal differentiation in the DG at 4 weeks after
theprogenitorproliferation,althoughall the otherparameters ofthe
neurogenesis examined remained unaltered in sdy2/2 mice when
compared to those in control mice (sdy+/+). This finding indicates




A deletion within the homologous gene in mice accounts for the
phenotype known as ‘‘sandy’’ (sdy2/2), which is characterized by
albinism and bleeding disorders [17]. This deletion is from
nucleotide 3701 of intron 5 to nucleotide 12377 of intron 7, and
essentially results in the total loss of dysbindin. We confirmed this
lack of dysbindin protein in the sdy2/2 mouse hippocampus by
Western blot analysis (Figure 1).
Progenitor proliferation
To evaluate progenitor cell proliferation in the DG as well as in
the entire hippocampus, bromodeoxyuridine (BrdU) was injected
intraperitoneally both in sdy2/2 and control (sdy+/+) mice (4
months old female mice, n=4) and the BrdU-labeled cells were
counted in mouse hippocampus killed 4 h after the injection. No
significant difference was observed between the two groups in terms
of the number of BrdU-labeled cells in the DG (sdy+/+ mice,
573626; sdy2/2 mice, 663687; p.0.05) (Figure 2, 4 h),
suggesting that BrdU bioavailability was similar in both. The
distribution of the dividing cells in the hippocampus of the sdy2/2
micewas not obviouslydifferentfromthat seen insdy+/+ mice.The
cellswerepredominantlyfoundinclustersatthe borderbetweenthe
granular layer (GL) and the hilus (HL) (i.e., subgranular layer: SGL)
of the DG (Figure S1).
Progenitor survival
ThesurvivalofBrdU-incorporatedprogenitorcellsat4monthsold
female mice was also examined in the DG 1 (n=4), 4 (n=8) and 8 w
(n=3) after the last BrdU injection. In the SGL, estimates of the total
BrdU-positive populations were 1,1536144 (1 w), 6256417 (4 w),
and 6476300 (8 w) in sdy2/2 mice and 1,2826175 (1 w), 448669
(4 w), and 652695 (8 w) in sdy+/+ m i c e( F i g u r e2 ,1w ,4w ,8w ) ,
with no statistically significant differences between groups.
Progenitor differentiation
To further examine the effects of dysbindin depletion,
differentiation was examined at 4 w after BrdU injection by
concurrent immunolabelling for BrdU with neuronal (NeuN) or
glial (NG2) markers. NG2 was preferred not only because it serves
as a marker for oligodendrocyte progenitor cells (OPCs), but also
because OPCs constitute the major dividing glial cell population of
the adult CNS [18]. NG2-positive OPCs are distinct from
neurons, mature oligodendrocytes, astrocytes, and microglia, and
are distributed throughout the gray and white matter [19]. No
significant difference was found between groups in either the
number or the percentage of BrdU-positive cells that co-labeled
for NG2 (Figure S2) in the DG (data not shown); this was also true
for other areas of the hippocampus as well (CA1 – 3) (Figure 3).
We found that an equal number of BrdU-positive cells co-
labeled with NeuN in the SGL in both the sdy2/2 (329627) and
sdy+/+ (326640) mice 4 w after the last BrdU injection. However,
the percentage of BrdU-positive cells that co-labeled with NeuN
was significantly less (215%, p,0.01) in sdy2/2 mice
(71.368.3%) than in sdy+/+ mice (87.065.3%) (Figure 3), mostly
due to the increased, albeit insignificant, number of BrdU-positive
cells in the SGL of sdy2/2 mice (Figure 2).
Figure 1. Lack of dysbindin-1 expression in the hippocampus
of sdy2/2 mice. Homogenates from the hippocampus region of
control mice (Ctrl) and sdy2/2 mice (Dys KO) were subjected to
Western blotting. Primary antibody: a monoclonal mouse dysbindin
antibody (1:1000); secondary antibody: an anti-mouse HRP-linked
antibody (1:2000).
doi:10.1371/journal.pone.0015886.g001
Figure 2. The survival of newborn cells in the SGL of sdy2/2
mice. The number of thymidine analogue bromodeoxuridine (BrdU) -
incorporated cells was not significantly different in the granular cell
layer (GL) between sdy+/+ (Ctrl) and sdy2/2 (Dys KO) mice at any time
point (4 h, 1 w, 4 w, and 8 w). The data are shown as the mean 6 s.d.
doi:10.1371/journal.pone.0015886.g002
Figure 3. Reduced rate of neuronal differentiation of newborn
cells in sdy2/2 mice. The rate of NeuN-positive newborn cells in the
granular cell layer (GL) of sdy2/2 (Dys KO) mice was significantly lower
compared to that of sdy+/+ mice (Ctrl) (*p=0.01), as opposed to that of
NG2-positive cells in other areas of the hippocampus (CA1 – 3) at 4
weeks after thymidine analogue bromodeoxuridine (BrdU) injection.
The data are shown as the mean 6 s.d.
doi:10.1371/journal.pone.0015886.g003
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Neurogenesis in adult mammalian brains actively occurs at the
subventricular zone of the lateral ventricles and at the SGL of DG
in the hippocampus. In the present study, we investigated the
nature of hippocampal neurogenesis in spontaneously occurring
dysbindin null (sdy2/2) mice. We found that, although the
numbers of new neurons generated in the SGL of sdy2/2 mice
are almost equal to those of sdy+/+ mice, the rates of neuronal
differentiation stemming from newly generated cells are signifi-
cantly lower in sdy2/2 mice.
Newborn cells in the SGL initially receive GABAergic signalling
from interneurons within the DG [20]. GABA initially induced the
depolarization of immature newborn cells within the first 2–3 w
after birth, depending on the gradient of Cl
2 levels (i.e.,
intracellular Cl
2 levels are higher than extracellular ones) [21–
24]. These cells then gradually migrate into the granular layer and
mature as a result of the shift from depolarization to hyperpolar-
ization. Signaling through the NMDA receptor plays a cell
autonomous role in the survival of neuronally differentiating
newborn cells during the first 3,4 w after the birth, which
coincides with the formation of dendritic spines and functional
glutamatergic inputs (Figure 4) [20,25–28].
Although glutamate levels in the entire hippocampal formation
of sdy2/2 mice remain unaltered compared with those of sdy+/+
mice [15], the expression levels of dysbindin-1 reduced in the
DGiml of schizophrenia cases while those of the vesicular
glutamate transporter (VGluT-1), a glutamate terminal marker,
increased [7], indicating the abnormal glutamate transmission in
the DGiml in schizophrenia patients (Figure 4). Moreover,
sdy2/2 mice exhibited impaired learning in the Morris water
maze and T-maze, as well as long-term memory retention deficits
in the Barnes circular maze test [15,16,29], which is dependent
upon a correctly hippocampal functioning and, in part, on the
neurogenesis occurring therein [28]. Collectively, our finding that
the rate of neuronal differentiation of 4 w-old newborn cells was
lower in the DG of sdy2/2 mice may explain not only the
behavioral abnormalities observed in the sdy2/2 mice [15,16,29]
but also, at least in part, the cognitive, memory or IQ
abnormalities associated with genetic variations in human [12–
14,30–33] and with histopathological abnormalities found in the
postmortem brains of schizophrenia patients [5,7,8]. Thus, further
study of dysbindin-1 genotypes in relation both to specific
schizophrenia subtypes and to cognitive endophenotypes are
warranted, as does an in-depth investigation of the role of
dysbindin in glutamate neurotransmission and in other neuronal
functions in the brain.
Materials and Methods
Animals
The experiments were largely done on material from a
previously published study [15]. ‘‘Sandy’’ (sdy2/2) mice were
raised at The Jackson Laboratory, Bar Harbor, ME. Sandy mice
have an autosomal recessive coat color mutation that arose
spontaneously in the inbred DBA/2J strain. Both sdy2/2 mice
and wild-type mice derived from heterozygote crossings were used
in all experiments. All animals were housed in humidity- and
temperature-controlled rooms with a 12-hour (hr) light cycle with
free access to food and water. All protocols were approved by the
Animal Care and Use Committee of the Tokyo Institute of
Psychiatry.
Western blotting
Following deep anesthetization with sodium pentobarbital, the
hippocampus was dissected from each mouse. Hippocampal
tissues were homogenated in TNE buffer (20 mM tris-HCl,
pH 7.5, 150 mM NaCl, and 1 mM EDTA) containing 1% NP-40
and RIPA buffer and protease inhibitor cocktail (Roche, Sydney,
Australia) and centrifuged at 15,0006g for 10 min. Lysates were
boiled with SDS sample buffer (0.125 M Tris-HCl, pH 6.8, 10%
2-mercaptoethanol, 4% SDS, 10% sucrose, and 0.004% bromo-
pheonl blue) for 5 min and subjected to SDS–PAGE. Proteins
were separated on SDS–PAGE and electrotransferred onto
Immobilon-P Transfer Membranes (MILLIPORE, Billerica,
USA). Membranes were incubated in PBS containing 5% skim
milk and 0.05% Tween 20 for 1 h and blotted with primary
antibodies at 4uC overnight. An anti-dysbindin monoclonal
antibody (1:1000) was used as a primary antibody. Mouse
monoclonal anti-dysbindin antibody was produced using GST-
fused human dysbindin as antigen, as previously described [34,35].
The membranes were incubated with an anti-mouse HRP-linked
secondary antibody (1:2000, Cell Signalling Technology) for 1 h.
Proteins were detected with an ECL kit (Amersham Biosciences,
Buckinghamshire, UK) and were then exposed to X-ray films,
according to the manufacturer’s protocol.
Bromodeoxyuridine administration
Bromodeoxyuridine (BrdU; Sigma, St. Louis, MO) was
dissolved in phosphate buffer saline (PBS), pH 7.4, at a
concentration of 10 mg/ml and filter sterilized. Mice were divided
into four treatment groups (Group-I , Group-IV). In Group-I,
mice received one injection of BrdU (50 mg/g of body weight, i.p.)
and were killed 4 h later. In Group-II to -IV, mice received daily
injections of BrdU (50 mg/gm of body weight, i.p.) for 3
consecutive days. The mice were then killed 1 (Group-II), 4
(Group-III), or 8 (Group-IV) weeks (w) after the final injection.
Tissue processing
The animals were anesthetized and transcardially perfused with
PBS followed by 4% paraformaldehyde in PBS. Brains were
removed, post-fixed for 1 day at 4uC, and then cryoprotected
Figure 4. Effect of lack of dysbindin-1 expression on the adult
hippocampal neurogenesis. Newborn cells (blue) in the dentate
gyrus of sdy2/2 (Dys KO) may receive abnormal glutamate inputs
within the inner molecular layer (DGiml, orange) due to the lack of
dysbindin-1 expression during the critical periods for neuronal
differentiation (during the first 3,4 w from the birth), resulting in the
reduced rate of neuronal differentiation. GL and HL are granule cell
layer and hilus, respectively.
doi:10.1371/journal.pone.0015886.g004
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freezing microtome through the hippocampus at 40 mm. Four 1-
in-5 series were collected, plated onto glass slides, and stored at
230uC until histochemical analysis.
BrdU detection
To allow for the detection of BrdU-labeled cells (see below),
sections were pretreated for 30 min in 2N HCl at 37uCt o
denature DNA. The sections were then incubated for 10 min in
100 mM sodium borate, pH 8.5, to neutralize the residual acid.
Immunofluorescence
Sections were incubated for 30 min in PBS containing 5% goat
serum and 0.4% Triton X-100. Using the same buffer solution, the
sections were incubated overnight at 4uC in primary antibodies
(monoclonal rat anti-BrdU (Harlan Sera-Lab); polyclonal rabbit
anti-NG2 (Chemicon, Temecula, CA); monoclonal mouse anti-
neuron-specific nuclear protein (NeuN; Chemicon)), followed by
2 h at room temperature in corresponding fluorochrome-conju-
gated goat secondary antibodies (anti-mouse FITC, anti-mouse
rhodamine Red-X (RRX), anti-rabbit Cy5, anti-rabbit FITC, anti-
rabbit RRX, and/or anti-rat FITC; all from Jackson ImmunoR-
esearch). Each of the above steps was followed by four 5-min rinses
in PBS. The sections were mounted onto gelatin-coated slides,
dried, and coverslipped with ProLong antifade medium (Molec-
ular Probes, Eugene, OR).
Cell counting
Cell counts were performed by an observer who was unaware of
the treatment status of the animals. For each animal, a complete
series of 1-in-5 sections was analyzed with a light microscope at
600 x magnification. The number of immunoreactive cells was
counted in the granular layer (GL) (4 h, 1 w, 4 w, and 8 w) and in
the entire hippocampus (4 w). We defined the GL as the granular
cell layer plus the areas ,10 mm deep in the subgranular zone and
5 mm deep in the molecular layer of the DG. The total number of
BrdU-positive cells was estimated by multiplying the number of
profiles by 5. For cell phenotyping, BrdU-positive cells were
analyzed for colocalization with NeuN (in the GL) or NG2 (in the
hippocampus). Data were analyzed by ANOVA followed by
Scheffe ´’s test for post hoc multiple comparisons (Figure 2 and 3).
This was done for the two groups, normal controls (sdy+/+) and
‘‘Sandy’’ (sdy2/2) mice.
Supporting Information
Figure S1 BrdU-positive cells in dentate gyrus (DG) of sdy2/2
mice. Sections were the DG of sdy2/2 mice after 4 weeks from
the last thymidine analogue bromodeoxuridine (BrdU) injections.
BrdU-incorporating cells (green) were located mostly between the
granular layer (GL) and the hilus (HL). Nuclei were visualized by
using Topro-3 (Invitrogen, blue). Images were collected on high-
resolution confocal microscopy (LSM510 excitator, Zeiss). Confo-
cal z stacks were captured for each section (0.76–0.78 mm
increments) using a 20x objective (C-Apochromat, Zeiss).
Composite images were reconstructed using Imaris 5.0.3 software
(Zeiss). Scale bars represent 100 mm.
(TIF)
Figure S2 NG2-positive oligodendrocyte progenitor cells
(OPCs) in the hippocampus of sdy2/2 mice. Sections were the
hippocampus of sdy2/2 mice after 4 weeks from the last
thymidine analogue bromodeoxuridine (BrdU) injections. NG2
labeling is shown in red (arrow heads). Arrows indicate BrdU-
positive (green), NG2-positive OPCs. Nuclei were visualized by
using Topro-3 (Invitrogen, blue). Images were collected on high-
resolution confocal microscopy (LSM510 excitator, Zeiss). Confo-
cal z stacks were captured for each section (0.36 mm increments)
using a 40x water immersion objective (C-Apochromat, Zeiss).
Composite images were reconstructed using Imaris 5.0.3 software
(Zeiss). Scale bars represent 50 mm.
(TIF)
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